International Scholarly Research Notices / 2014 / Article / Tab 1

Research Article

p16 Expression Is Lost in Severely Atypical Cellular Blue Nevi and Melanoma Compared to Conventional, Mildly, and Moderately Atypical Cellular Blue Nevi

Table 1

Patient clinical characteristics, including age, gender, location of tumor, and follow-up data.

DiagnosisAgeSexLocationClinical follow-up

Benign CBN21FArmN/A
Mildly atypical CBN32FLegN/A
Mildly atypical CBN24MArmN/A
Mildly atypical CBN63MArmN/A
Mildly atypical CBN28FScalpN/A
Mildly atypical CBN87MEarN/A
Moderately atypical CBN35MScalpN/A
Moderately atypical CBN78FFaceN/A
Moderately atypical CBN51FButtockN/A
Moderately atypical CBN25MLegN/A
Severely atypical CBN49FBackNo recurrence after 21 months
Severely atypical CBN51FLegNo follow-up since diagnosis
Severely atypical CBN23MChestLost to follow-up
Severely atypical CBN38FButtockLost to follow-up
Severely atypical CBN57FButtockNo follow-up since diagnosis
Superficial spreading melanoma59MBackNo recurrence after 24 months
Superficial spreading melanoma68FArmNo recurrence after 20 months
Melanoma in transit metastasis83FArmMetastatic disease
Spitzoid melanoma24FChestNo recurrence after 12 months
Melanoma in situ54MToeNo recurrence after 22 months
Superficial spreading melanoma32MBackNo recurrence after 16 months
Superficial spreading melanoma60MBackLost to follow-up
Superficial spreading melanoma73MNeckNo recurrence after 18 months
Nevoid melanoma56FBackLost to follow-up
Superficial spreading melanoma22FLegNo recurrence after 16 months
Spitzoid melanoma41MBackNo recurrence after 22 months
Superficial spreading melanoma23FArmNo recurrence after 11 months
Malignant CBN61FFootNo recurrence after 12 months
Malignant CBN13MFaceNo follow-up since diagnosis
Malignant CBN86MBackIn transit metastasis
Malignant CBN recurrence66MFaceN/A

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.